Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Abaloparatide Injection in Healthy Adults
NCT06753864Phase 1Not yet recruiting
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Jan 2025
- Primary completion
- Jan 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of abaloparatide in osteoporosis (2 arms), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoints: Peak Plasma Concentration at 4 hours, Area under the plasma concentration versus time curve from time 0 to time t at 4 hours and 1 more. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
abaloparatide
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT06753864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06753864.